Poor adult tuberculosis treatment outcome and associated factors in Gibe Woreda, Southern Ethiopia: An institution-based cross-sectional study.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
09
2021
accepted:
22
12
2021
entrez:
24
3
2023
pubmed:
25
3
2023
medline:
25
3
2023
Statut:
epublish
Résumé
Tuberculosis (TB) remains a major medical and public health problem throughout the world, especially in developing countries including Ethiopia. Its control program is currently being challenged by the spread of drug-resistant TB, which is the result of poor treatment outcomes. Hence, this study assessed poor adult TB treatment outcomes and associated factors in Gibe Woreda, Southern Ethiopia. An institution-based cross-sectional study was conducted from March 1, 2020 to March 30, 2020, using a standard checklist to review clinical charts of TB patients who enrolled on first-line TB treatment under DOTS between June 2016 and June 2019. Poor treatment outcomes constituted death during treatment, treatment failure, and loss to follow-up (LTFU). Descriptive statistics were used to describe the characteristics of study participants. A binary logistic regression model was fitted to identify factors influencing treatment outcome and adjusted odds ratios with a 95% confidence interval were reported. The statistical significance of all tests in this study was declared at P-value <5%. A total of 400 adult TB patients were participated. The mean age of study participants was 39.2±16.7 years, 55.5% were males and 79.8% were pulmonary tuberculosis cases. Regarding the treatment outcomes, 58% completed treatment, 27.5% cured, 9.3% were LTFU, 3.2% died, and 2.0% failed. The overall poor treatment outcome was 14.5% (95% CI: 11.1-17.9). Age (aOR = 1.02; 95%CI: 1.01-1.04), male gender (aOR = 1.82; 95% CI: 0.99-3.73), travel ≥ 10 kilometres to receive TB treatment (aOR = 6.55; 95% CI: 3.02-14.19), and lack of family support during the course of treatment (aOR = 3.03; 95% CI: 1.37-6.70), and bedridden baseline functional status (aOR = 4.40; 95% CI: 0.96-20.06) were factors associated with poor treatment outcome. Successful TB treatment outcome in this study area was below the national TB treatment success rate. To improve positive treatment outcomes, remote areas should be prioritized for TB interventions, and stakeholders in TB treatment and care should give special emphasis to adults over the age of 45 years, males, those who travel more than 10 kilometres to receive TB care, having bedridden baseline functional status and those who had no family support.
Identifiants
pubmed: 36962264
doi: 10.1371/journal.pgph.0000161
pii: PGPH-D-21-00626
pmc: PMC10021194
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0000161Informations de copyright
Copyright: © 2022 Mengesha et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Tuberc Res Treat. 2019 Apr 01;2019:1503219
pubmed: 31057963
Infect Drug Resist. 2020 Oct 06;13:3423-3429
pubmed: 33116661
BMC Health Serv Res. 2021 Jun 30;21(1):627
pubmed: 34193133
BMC Res Notes. 2016 Feb 12;9:89
pubmed: 26868489
J Pathog. 2018 Apr 03;2018:7104921
pubmed: 29850257
Ethiop J Health Sci. 2018 May;28(3):347-354
pubmed: 29983535
Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7
pubmed: 12569078
PLoS One. 2020 Apr 29;15(4):e0232468
pubmed: 32348358
BMC Public Health. 2019 Dec 10;19(1):1658
pubmed: 31822286
BMC Infect Dis. 2017 Feb 8;17(1):132
pubmed: 28178936
PLoS One. 2019 Jan 10;14(1):e0210422
pubmed: 30629684
BMC Infect Dis. 2013 Jul 01;13:297
pubmed: 23815342
Afr Health Sci. 2016 Sep;16(3):663-670
pubmed: 27917197
BMC Res Notes. 2018 Jan 15;11(1):25
pubmed: 29335004
J Public Health Res. 2021 Apr 21;10(3):
pubmed: 33882659
BMC Infect Dis. 2019 May 28;19(1):474
pubmed: 31138129
Trop Med Health. 2020 Feb 18;48:9
pubmed: 32099523
PLoS One. 2018 Oct 26;13(10):e0206227
pubmed: 30365530
PLoS One. 2018 Mar 19;13(3):e0194675
pubmed: 29554144
Tuberc Res Treat. 2014;2014:726193
pubmed: 24891948
Braz J Infect Dis. 2016 Nov - Dec;20(6):635-636
pubmed: 27553661
BMC Res Notes. 2018 Oct 1;11(1):691
pubmed: 30285907
BMC Pulm Med. 2018 Feb 20;18(1):37
pubmed: 29463234
Int J Tuberc Lung Dis. 2010 Aug;14(8):973-9
pubmed: 20626941